Literature DB >> 1909705

Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.

B C Fauser1, T D Pache, S W Lamberts, W C Hop, F H de Jong, K D Dahl.   

Abstract

Serum steroid, gonadotropin, and alpha-subunit levels were assessed in 35 women with cycle abnormalities [11 with and 24 without polycystic ovarian disease (PCOD) according to strict clinical and biochemical criteria] and 8 regularly cycling women in the early (cycle day 3 or 4) and mid (cycle day 7 or 8) follicular phase. LH and FSH levels were estimated using two immunological techniques [RIA and immunoradiometric assay (IRMA)] and in vitro bioassays (BIO), using mouse Leydig cells and rat granulosa cells, respectively. In PCOD patients mean alpha-subunit, free androgen index [FAI; testosterone x 100/sex hormone-binding globulin (SHBG)], androstenedione, estrone, and estradiol (E2) were significantly elevated compared to levels in the early follicular phase of control cycles and non-PCOD patients. In addition, in PCOD patients mean IRMA-LH and RIA-LH levels were distinctly increased (2.8- to 3.6 fold, respectively; both comparisons, P less than 0.001) compared to control values, but in the same order of magnitude (1.3- to 1.4-fold increments) as that in non-PCOD patients. However, the median BIO-LH level in PCOD patients was 5.9-fold higher than that in non-PCOD patients and 4.0-fold higher than the BIO-LH in the early follicular phase of control women. Consequently, the median BIO/IRMA-LH ratio was 4.8-fold higher in PCOD patients compared to non-PCOD patients. In women with cycle abnormalities, individual BIO/IRMA-LH ratios correlated with BIO-LH (rs = 0.48), FAI (rs = 0.39), free estrogens (E2/SHBG ratios; rs = 0 0.47), and dehydroepiandrosterone sulfate (rs = 0.60) concentrations. Mean IRMA-, RIA-, and BIO-FSH levels and BIO/IRMA-FSH ratios were not significantly different when various groups were compared. Although RIA- and IRMA-LH levels showed good correlation (rs = 0.88), RIA-LH levels were consistently higher, resulting in distinctly higher RIA-LH/FSH ratios (mean, 4.5) compared to IRMA-LH/FSH ratios (median, 1.8) in PCOD patients.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909705     DOI: 10.1210/jcem-73-4-811

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Genetic analysis of the follicle stimulating hormone receptor gene in women with polycystic ovary syndrome.

Authors:  F Orio; E Ferrarini; T Cascella; A Dimida; S Palomba; E Gianetti; A Colao; P Agretti; P Vitti; G Lombardi; A Pinchera; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 2.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

3.  Hyper response to ovarian stimulation affects the follicular fluid metabolomic profile of women undergoing IVF similarly to polycystic ovary syndrome.

Authors:  Fernanda Bertuccez Cordeiro; Thaís Regiani Cataldi; Beatriz Zappellini de Souza; Raquel Cellin Rochetti; Renato Fraietta; Carlos Alberto Labate; Edson Guimarães Lo Turco
Journal:  Metabolomics       Date:  2018-03-16       Impact factor: 4.290

4.  Polycystic ovary syndrome and risk of uterine leiomyomata.

Authors:  Lauren A Wise; Julie R Palmer; Elizabeth A Stewart; Lynn Rosenberg
Journal:  Fertil Steril       Date:  2007-01-22       Impact factor: 7.329

5.  Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.

Authors:  Subeka Abraham Gnanadass; Yogamaya Divakar Prabhu; Abilash Valsala Gopalakrishnan
Journal:  Arch Gynecol Obstet       Date:  2021-01-13       Impact factor: 2.344

6.  Frequency of nodular goiter and autoimmune thyroid disease in patients with polycystic ovary syndrome.

Authors:  Cevdet Duran; Mustafa Basaran; Orkide Kutlu; Zehra Kucukaydin; Suleyman Bakdik; Ferda Sevimli Burnik; Uysaler Aslan; Sami Said Erdem; Samil Ecirli
Journal:  Endocrine       Date:  2014-12-19       Impact factor: 3.633

7.  Follicular fluid lipid fingerprinting from women with PCOS and hyper response during IVF treatment.

Authors:  Fernanda Bertuccez Cordeiro; Thaís Regiani Cataldi; Lívia do Vale Teixeira da Costa; Camila Bruna de Lima; Juliana Stevanato; Daniel Suslik Zylbersztejn; Christina Ramires Ferreira; Marcos Nogueira Eberlin; Agnaldo Pereira Cedenho; Edson Guimarães Lo Turco
Journal:  J Assist Reprod Genet       Date:  2014-11-06       Impact factor: 3.412

Review 8.  Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome.

Authors:  J E Hall; A E Taylor; F J Hayes; W F Crowley
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

9.  Microvesicle-mediated release of soluble LH/hCG receptor (LHCGR) from transfected cells and placenta explants.

Authors:  Anne E Chambers; Paul F Stanley; Harpal Randeva; Subhasis Banerjee
Journal:  Reprod Biol Endocrinol       Date:  2011-05-15       Impact factor: 5.211

10.  Low- and Fully N-Glycosylated Gonadotropins Circulating in Women With Polycystic Ovary Syndrome.

Authors:  Leif Wide; Tord Naessén; Inger Sundström-Poromaa; Karin Eriksson
Journal:  J Endocr Soc       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.